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Summary
Objective
The differential effect of GLP-1 agonist Exenatide on functional connectivity of the
nucleus tractus solitaries (NTS), a key region associated with homeostasis, and on
appetite-related behaviours was investigated in women with normal weight compared
with women with obesity.
Methods
Following an 8-h fast, 19 female subjects (11 lean, 8 obese) participated in a 2-d double
blind crossover study. Subjects underwent functional magnetic resonance imaging at
fast and 30-min post subcutaneous injection of 5 μg of Exenatide or placebo. Functional
connectivity was examined with the NTS. Drug-induced functional connectivity changes
within and between groups and correlations with appetite measures were examined in a
region of interest approach focusing on the thalamus and hypothalamus.
Results
Women with obesity reported less hunger after drug injection. Exenatide administration
increased functional connectivity of the left NTS with the left thalamus and hypothalamus
in the obese group only and increased the correlation between NTS functional connectiv-
ity and hunger scores in all subjects, but more so in the obese.
Conclusions
Obesity can impact the effects of Exenatide on brain connectivity, specifically in the NTS
and is linked to changes in appetite control. This has implications for the use of GLP-1
analogues in therapeutic interventions.
Keywords: Brain, GLP-1, hunger, obesity.
Introduction
Glucagon-like Peptide 1 (GLP-1) receptor agonists have
shown to improve glucose control, decrease food intake,
accelerate weight loss and increase satiety (1–3).
Increases in post-prandial GLP-1 levels have also been
implicated in the observed weight loss following bariatric
surgery (1,4). Because of these effects, the role of GLP-
1 in the regulation of food intake has been evaluated cen-
trally in the brain particularly in the hypothalamus and
brain stem where it affects appetite and food intake and
peripherally in the ileum where it affects satiety (5). It has
also been shown that peripherally administered GLP-1
can reach the brain via leaks in the blood brain barrier (5).
Glucagon-like Peptide 1 is primarily released from L
cells in the distal gut, but it is also produced in the vagal
nucleus of the solitary tract (NTS) (6), a brainstem region
that plays a central role in the regulation of satiety. The
NTS sends projections to the hypothalamus and intero-
ceptive regions within the brain’s homeostatic network
(including thalamus and insular cortex) (7,8). Vagal signal-
ling to the hypothalamus and thalamus is likely to play a
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crucial role in mediating the impact of GLP-1 on ingestive
behaviour (9), and abnormalities in this signalling have
been implicated in the pathophysiology of obesity (10).
While findings from rodent studies emphasize the impor-
tant interactions between GLP-1 and NTS on body weight
control and human studies have shown reduced appetite
in human subjects in response to Liraglutide and other
GLP-1 agonists, the central mechanisms of this molecule
are incompletely understood (9,11).
Functional brain imaging techniques help bridge the
gap between clinical observation and underlying neurobi-
ological mechanisms. Measuring intrinsic brain oscilla-
tions during resting conditions has demonstrated altered
functional connectivity of specific brain regions in clinical
conditions including obesity (12). Altered NTS functional
connectivity within the hypothalamus while looking at
images of palatable food after consuming a caloric bever-
age has been previously demonstrated in women with
obesity (13). These brain changes were correlated with
alterations in taste ratings determined by a questionnaire,
linking functional connectivity alterations in the NTS and
hypothalamus to ingestive behaviour (13).
Based on previous observations of differential func-
tional connectivity in individuals with obesity compared
with those with normal weight, the current study aimed
to measure the impact of the GLP-1 analogue Exenatide
on the intrinsic functional connectivity of the NTS with
other brain regions. By studying resting state activity in
healthy female participants with normal weights and
obesity, the current study aimed to test the following
hypotheses: (i) Exenatide changes functional connectivity
between NTS and the thalamus and hypothalamus; (ii)
these drug-induced changes in functional connectivity
are different in women with obesity compared with
women with normal weight; and (iii) the alterations in
NTS functional connectivity are correlated with behav-
ioural measures related to eating such as calories
consumed at a meal and subjective feelings of hunger.
Methods
Subject selection
Nineteen healthy female subjects, ages 18–40, were
recruited through the G. Oppenheimer Center for Neuro-
biology of Stress and Resilience from flyers and website
advertisements. The sample included 11 women with
normal weight (mean age: 25.09 ± 4.83 years old) with a
mean body mass index (BMI) = 21.38 kg/m2
(range = 19.52–24.74 kg/m2) and 8 women with obesity
(mean age: 26.62 ± 7.63 years old) with mean
BMI = 34.08 kg/m2 (range = 30.72–37.56 kg/m2). All
subjects were right-handed, pre-menopausal and in the
follicular phase of the menstrual cycle by self-report and
classified as healthy after a clinical assessment that
included a modified Mini-International Neuropsychiatric
Interview Plus 5.0 (14), a brief structured interview for
major Axis I psychiatric disorders in Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(15) and International Statistical Classification of Diseases
10th Revision (16). Further exclusion criteria included
pregnancy, substance abuse, tobacco dependence,
evidence of cardiovascular, gastrointestinal, hepatic,
neurologic or psychiatric illness, diabetes, high blood glu-
cose levels (<200 mg/dL), strenuous exercise (more than
8 h/week) and any eating disorders. Subjects were also
excluded if they were currently on medication such as an-
algesics or antidepressants, had used any diet aids in the
last month, had undergone any bariatric surgeries, were
not able to undergo an MRI or could not eat one of three
meal options. Throughout the study, subjects were asked
to report any feelings of nausea.
The subjects provided written informed consent and all
procedures were reviewed and approved by the UCLA
Medical Institutional Review Board.
Study paradigm
The subjects came in for three visits, a screening visit to
determine their eligibility followed by two nearly identical
MRI visits where they received either the drug or saline
placebo injection in a randomized, double-blinded fash-
ion. All scanning began in the morning after at least 8 h
of fasting (the subjects did not eat breakfast). Blood
glucose levels were determined to be within the range of
65–126 mg/dL. Brain scans were obtained at a pre-
injection baseline and at 25 min after drug/placebo
administration. Blood samples were obtained at fasting,
before the drug/placebo injection and at 25, 35 and
60 min after drug administration. Scores for hunger/
satiety levels using a 100-point visual analogue scale
were obtained at the same time as the blood draws. After
scanning, the subjects were taken to a general clinical
research area and given a pre-selected 1000 calorie meal
composed of 30% fat, 20% protein and 50% carbohy-
drates and were instructed to ‘eat until you are full’. Meals
were measured before and after consumption to deter-
mine calories consumed.
The basic protocol is reflected in Figure 1.
MRI protocol
Before placement into the scanner, the subjects com-
pleted the Hospital Anxiety and Depression questionnaire
(17). Following placement in the scanner, the subjects
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underwent a 3-min alignment true fast imaging with
steady-state free precession (TRUFI) scan before a base-
line 10-min resting state scan during which they were
asked to lie still with their eyes closed and instructed
not to fall asleep. After the resting scan, the subjects were
removed from the scanner to receive either a subcutane-
ous injection of 5 μg of Exenatide or a 0.5-cc injection of
saline (placebo) in the deltoid (upper arm) area. After the
injection, the subjects were moved back into the scanner
for a 9-min standard T1-weighted magnetization-
prepared rapid acquisition gradient echo structural scan
followed by a 10-min resting state scan that was com-
pleted 25–30 min after the injection.
Resting state data acquisition and pre-processing
Functional MRI resting state scans were acquired on a
Siemens 3 Tesla Trio scanner. The 10-min scans were
acquired with an echo planar sequence with the
following parameters: TE = 28 ms, TR = 2,000 ms, flip
angel = 77°, FOV = 220 mm, slices = 40, slice
thickness = 4.0 mm. Slices were obtained with whole-
brain coverage.
Image processing and data analysis were performed
by using Statistical Parametric Mapping 8 (SPM8) software
(Wellcome Department of Cognitive Neurology, London).
Processing was done through the SPM toolbox, Data
Processing Assistant for Resting-State fMRI (18). Data
were slice-time, motion corrected, and nuisance covari-
ate regression was preformed to minimize physiological
noise by using six head motion parameters, white matter
signal and cerebrospinal fluid signal. Data were spatially
normalized to the Montreal Neurological Institute tem-
plate by using the magnetization-prepared rapid acquisi-
tion gradient echo structural scan, which was acquired
with the following parameters: TE = 3.26 ms,
TR = 2,200 ms, slices = 176, slice thickness = 1.0 mm,
voxel size = 1 × 1 × 1 mm. Spatial smoothing with a
4-mm3 Gaussian kernel occurred after calculation of
connectivity maps (18).
Blood sample processing
Blood samples were sent to outside laboratories for pro-
cessing. Tamdem Labs California used an enzyme-linked
immunosorbent assay to determine plasma concentration
of Exenatide (19,20).
Data analyses
Clinical/behavioural characteristics
Analyses of clinical characteristics (age, BMI, education,
anxiety and depression), behavioural measures (calorie
consumption and fullness questionnaires) and blood
levels of Exenatide were performed in SPSS 22 (21). Clini-
cal characteristics were evaluated by using t-tests to
compare group means (lean; obese). Anxiety and depres-
sion scores were compared separately for each day
(screening day, drug day and placebo day). Levels of
Figure 1 Basic scan day protocol. Subjects were brought in after at least 8 h of fasting. Scans were done both pre-subcutaneous and post-sub-
cutaneous injection of either drug or saline placebo. After scanning, subjects were given a meal. Blood draws and questionnaires were given
before scanning and 35 and 60 min after injection.
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Exenatide were compared between each group (lean;
obese) by both day (drug; placebo) and time post injec-
tion (35 min; 60 min). In order to determine calorie
consumption, a general linear model was run looking at
group (lean: obese) × day (drug; placebo) by using blood
levels of Exenatide as a covariate. Behavioural measures
from the fullness questionnaire were analysed with
ANOVAs looking at group (lean; obese) × time (baseline;
35 min post injection, 60 min post injection) and changes
over time (i.e. 60 min post injection > 35 min post injec-
tion) for changes between days (drug day  placebo day).
Seed-based functional connectivity of the NTS
Using MarsBar (22), an NTS seed cluster was defined by a
4-mm sphere around the peak NTS coordinate deter-
mined by Kilpatrick et al. (13). Left and right clusters were
defined separately. The functionally defined NTS cluster
is simply referred to as the NTS in the Results and Discus-
sion sections. Fisher transformed maps of the bivariate
correlation between the NTS seed time course, and all
other voxels were created by using Data Processing As-
sistant for Resting-State fMRI (18) for the left and right
NTS. Based on significant results from Kilpatrick et al.,
this was done for a specific low-frequency band (0.01–
0.027 Hz) (13,23). The resulting functional connectivity
maps were analysed in a flexible factorial general linear
model in SPM8 to compare group data (obese; lean) × day
(drug; placebo) × scan (pre-injection; post injection). The
order of the drug day was included as a factor in the
model to account for any order effects. Age and blood
levels of Exenatide were used as covariates. Using a
region of interest approach similar to other studies
(12,24), contrasts were performed to identify regions
with altered connectivity with the NTS before or after
the drug versus placebo, looking at both within-group
and between-group differences. Anatomically based
ROIs were created by using the Wake Forest
University PickAtlas tookbox in SPM8. Hypothalamus
and thalamus ROIs were chosen based on previous liter-
ature, defining them as regions associated with the NTS
in hunger and satiety signalling (10). Images were
thresholded at p = 0.001, and uncorrected and small vol-
ume corrections were applied to determine significance at
p < 0.05, corrected for family wise error rate. False
discovery rate was applied to control for the type I error
inherent in testing multiple ROIs (25,26). Cluster size
was limited to Ke > 3.
Functional connectivity correlations with behaviour
A multiple regression model in SPM8 was used to deter-
mine group differences in the association of calorie
consumption and fullness questionnaire scores with
functional connectivity of the NTS seed regions and
designated ROIs described in the preceding texts.
Blood levels of Exenatide, age and order of the drug
day were used as covariates. The questionnaire re-
sponses selected for the correlational analysis were
those that showed significant group differences in the
behavioural SPSS analyses, which related to hunger.
Contrast images were created to identify drug-induced
changes in the correlation between functional connectiv-
ity and behavioural measure both within and between
groups, as well as differences at the pre-injection base-
line. Images were thresholded at p = 0.001, and uncor-
rected and small volume correction was employed to
determine significance of the region of interest at
p < 0.05 family wise error with additional false discovery
rate correction to account for multiple comparisons
(25,26). Cluster size was limited to Ke > 3.
Results
Clinical characteristics
There were no statistically significant group differences in
age or any clinical variable other than BMI (Table 1). With
all subjects in the clinically normal range, the two groups
did not differ on any visit in anxiety symptom scores
(screening: F = 3.46, p = 0.080; placebo day: F = 1.233,
p = 0.282; drug day: F = 3.28, p = 0.088) or depression
symptom scores (screening: F = 4.139, p = 0.058; pla-
cebo day: F = 0.370, p = 0.552; drug day: F = 0.306,
p = 0.558; Table 1).
Exenatide levels
Both groups showed significantly higher levels of
Exenatide in blood on the drug day compared with
placebo day at all time points (p < 0.001; Table SS1 and
Figure SS1). During the drug day, the lean group had
higher plasma levels of Exenatide than the obese group
both at 35 min (161 vs. 97.5 pg/mL), lean versus obese
(p = 0.004) and 60 min (238.3 vs. 147.5 pg/mL, lean vs.
obese p = 0.001) after injection, but both groups showed
an increase of the drug between those times (p = 0.007).
Due to the pharmacokinetic value differences between
the groups, all subsequent analyses used the level of
Exenatide in the blood as a covariate.
Glucose levels
All subjects combined on the drug day showed a de-
crease in mean blood glucose levels at both 35 min
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(77.35 vs. 86.56 mg/dL) and 60 min (75.87 vs.
86.56 mg/dL) after Exenatide injection compared with
the placebo day (p < 0.001). Both lean and obese
groups showed a significant reduction in mean blood glu-
cose levels on the drug day between baseline and both
35 and 60 min post injection [lean baseline (83.8 mg/dL)
vs. 35 min (75.90 mg/dL), p = 0.026; lean baseline vs.
60 min (73.78 mg/dL), p = 0.030; obese baseline
(90.57 mg/dL) vs. 35 min (79.43 mg/dL), p = 0.007; obese
baseline vs. 60 min (78.57 mg/dL), p = 0.004]. There were
no significant differences between lean and obese groups
(Figure SS2).
Hunger and appetite measures
There were no statistically significant group differences in
calorie consumption on drug (468.21 vs. 620.25 kcal
p = 0.109, F = 1.27) or placebo (569.10 vs. 652.81 kcal
p = 0.275, F = 2.86) days. However, trends suggest that
both groups consumed less calories on the drug day
and that the obese group consumed more calories on
both days than the lean group (Figure 2).
Regarding hunger scores, the only significant change
was seen in the obese group on the day of the Exenatide
injection (versus the placebo injection) when they
reported to be less hungry than the lean group 35 min
after drug injection (8.64 vs. 5.00; p = 0.035) and have
a greater decrease in hunger scores after eating the
Table 1 Subject clinical characteristics
Lean N = 11 Obese N = 8 F p-value
Age (year) Mean: 25.09
Range: 21–36
SD: 4.83
Mean: 26.62
Range: 19–39
SD: 7.63
0.538 0.598
BMI (kg/m2) Mean: 21.38
Range: 19.52–24.74
SD: 1.92
Mean: 34.08
Range: 30.72–37.56
SD: 2.35
168.54 <0.001**
Education Mean: 4.55
SD: 2.34
Mean: 4.00
SD: 1.78
0.305 0.588
HAD Anxiety
Screening Mean: 2.91
SD: 3.21
Mean: 5.50
SD: 2.67
3.46 0.080
Placebo day Mean: 3.00
SD: 4.05
Mean: 4.75
SD: 2.12
1.233 0.282
Drug day Mean: 2.54
SD: 3.59
Mean: 5.00
SD: 1.51
3.28 0.088
HAD Depression
Screening Mean: 0.727
SD: 1.01
Mean: 1.87
SD: 1.46
4.139 0.058
Placebo day Mean: 1.09
SD: 2.21
Mean: 1.63
SD:1.30
0.370 0.552
Drug day Mean:1.18
SD: 2.56
Mean: 1.75
SD: 1.58
0.306 0.588
BMI, body mass index; HAD, Hospital Anxiety and Depression. p-values significant: 0.05* and 0.01**.
Education scoring: 1 = 8th grade or less; 2 = Some high school; 3 = High school graduate; 4 = Some college; 5 = College graduate; 6 = Any post-
graduate work.
Figure 2 Calorie consumption of lean versus obese subjects of a
post-scan meal. Trends show that both lean and obese groups con-
sumed fewer calories on the day of the exenatide injection versus the
placebo day and that the obese group consumed more calories on
both days.
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provided meal (7.27 vs. 10.00; p = 0.025). No significant
group differences in hunger were observed before injec-
tion (Table 2). No group differences were observed for
satiety levels.
Functional connectivity of the NTS
No differences in functional connectivity were observed
at baseline between day and group. After Exenatide ad-
ministration, in comparison with the placebo, the obese
group demonstrated increased functional connectivity of
the left NTS with the left thalamus and left hypothalamus.
No drug-induced connectivity change was observed in
the lean group. For the right NTS seed, the obese group,
compared with the lean group, showed greater functional
connectivity with the left thalamus after drug administra-
tion versus the placebo (Table 3 and Figure 3).
NTS functional connectivity and behavioural
correlates
Calorie consumption
For all subjects combined, there was a significant in-
crease in the correlation between calorie consumption
and functional connectivity of the right NTS with the
right hypothalamus following Exenatide administration
(versus placebo; Table 4A and Figure 4A). No group dif-
ferences of significant correlations were observed before
or after the drug injection. No subject consumed the
entire meal.
Hunger ratings
At baseline, the lean group showed a statistically greater
correlation between hunger scores and functional con-
nectivity of the right NTS with the left thalamus [(10
16 16), p = 0.004, Ke = 87, z = 4.69] than the obese
group. After Exenatide injection (versus placebo), all sub-
jects combined demonstrated a positive correlation
between subjective feelings of hunger and functional con-
nectivity of the right NTS with the right hypothalamus. The
subjects with obesity had a statistically greater correlation
between the hunger ratings and functional connectivity
of the right NTS with the left thalamus compared with
subjects with normal weight. The subjects with obesity
showed a correlation between hunger scores and func-
tional connectivity of the left NTS with the left thalamus
(Table 4B and Figure 4B–D). No correlations were seen
between NTS connectivity and satiety scores.
Discussion
Exenatide administration, in comparison with placebo,
resulted in increased NTS functional connectivity with
the thalamus and hypothalamus in subjects with obesity.
Specifically, an Exenatide-induced increase in NTS
Table 2 Fullness questions
Q: How hungry do you feel?
Group Time point Mean SD
Lean Baseline 0 29.07
+35 min 8.63 16.14
+60 min 2.73 16.33
+35 > baseline 8.64 31.71
+60 > baseline 2.73 37.77
+60 > +35 min 7.27 18.08
Obese Baseline 8.75 36.03
+35 min 5.00 5.34
+60 min 2.50 3.78
+35 > baseline 3.75 38.89
+60 > baseline 6.25 34.10
+60 > +35 min 10.00 9.64
Group difference Time point F p-value
Lean vs. obese Baseline 0.344 0.565
+35 min 5.221 0.035
+60 min 0.777 0.390
+35 > baseline 0.091 0.766
+60 > baseline 0.044 0.837
+60 > +35 min 6.00 0.025
Q: How full do you feel?
Group Time point Mean SD
Lean Baseline 5.45 13.62
+35 min 4.55 16.35
+60 min 3.64 13.80
+35 > baseline 10.00 19.34
+60 > baseline 9.09 18.00
+60 > +35 min 1.36 26.00
Obese Baseline 0.625 21.78
+35 min 7.50 10.35
+60 min 3.12 6.51
+35 > baseline 8.12 22.67
+60 > baseline 3.75 21.84
+60 > +35 min 14.37 23.37
Group difference Time point F p-value
Lean vs. obese Baseline 0.555 0.467
+35 min 3.338 0.085
+60 min 1.635 0.218
+35 > baseline 3.52 0.078
+60 > baseline 1.97 0.178
+60 > +35 min 1.844 0.192
Asked the question ‘How hungry do you feel?’, the obese group re-
ported to be less hungry 35 min after Exenatide injection versus pla-
cebo. The obese group also had a greater decrease in hunger on the
drug day (versus placebo day) after eating the meal (vs. before the
meal). No group differences were observed with the question ‘How
full do you feel?’ All mean scores are drug day minus placebo day.
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functional connectivity was seen in the obese group only
between the left NTS with the left hypothalamus and thal-
amus. For the right NTS, the functional connectivity with
the left thalamus was statistically greater in the obese
group when compared with the lean group.
The brainstem, specifically the NTS, and the hypothal-
amus are regions associated with regulation of food
intake and ingestive behaviour (3). The bidirectional
connection between these two regions is involved in inte-
grating peripheral signals from hormones in the regulation
Table 3 Impact of Exenatide on NTS functional connectivity
Contrast Lean Obese Obese > lean Lean > obese Lean + obese
Region
L NTS functional connectivity
L HYP
Coordinate (6 4 12)
Cluster (Ke) 5
p-value 0.026*
z-score 3.38
R HYP
Coordinate
Cluster (Ke)
p-value
z-score
L thalamus
Coordinate (20 36 8) (14 26 16)
Cluster (Ke) 46 13
p-value 0.028* 0.055
z-score 4.86 3.77
R thalamus
Coordinate (10 24 12) (6 36 4)
Cluster (Ke) 7 13
p-value 0.054 0.108
z-score 3.79 3.56
R NTS functional connectivity
L HYP
Coordinate
Cluster (Ke)
p-value
z-score
R HYP
Coordinate
Cluster (Ke)
p-value
z-score
L thalamus (Decreased functional connectivity)
Coordinate (18 24 4) (10 16 18) 1016 16)
Cluster (Ke) 14 8 51
p-value 0.125 0.140 0.022*
z-score 3.51 3.47 4.51
R thalamus
Coordinate (8 8 12)
Cluster (Ke) 32
p-value 0.022*
z-score 4.47
Using the NTS as a seed, Exenatide administration resulted in greater functional connectivity in the obese group for both right and left seeds in a
low-frequency band (0.01–0.027 Hz) for hypothalamus and thalamus ROIs. For the left NTS, this change was not seen in the lean group and for
the right NTS; this change was greater in the obese than the lean group. Combining groups, greater functional connectivity was observed in the
left NTS. L, left; NTS, nucleus of the solitary tract; R, right.
*p-value observed after correction for multiple comparisons.
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of satiety (3), and differences in hypothalamus connectiv-
ity between individuals with obesity compared with those
with normal weights have been shown to be reduced after
successful bariatric surgery (27). This increased connec-
tivity in response to the drug suggests an Exenatide-
induced alteration of satiety signalling in individuals with
obesity. Previous reports have suggested a decreased
sensitivity to GLP-1 in obesity and have connected
reduced endogenous GLP-1 and reduced GLP-1 recep-
tor activation to weight gain (28). Imaging studies have
linked increased receptor availability to increased func-
tional connectivity in the brain (29). An exogenous
GLP-1 agonist might be working to overcome a
decreased sensitivity in obesity, and the Exenatide-
induced increase in functional connectivity observed in
this study is more so in the obese group could be
reflective of the drug’s ability to increase GLP-1 receptor
activity in a depressed system.
This study also showed that after Exenatide injection,
the obese group demonstrated significantly greater func-
tional connectivity between the NTS and the thalamus
compared with the lean group. Regions of the thalamus,
particularly the paraventricular area receive input from
the NTS, and these inputs are thought to play a role in
homeostatic regulation of food intake (30). A greater in-
crease in functional connectivity with the thalamus in the
obese group could indicate that Exenatide may modulate
homeostatic regulation of food intake differently in this
group compared with more lean individuals.
As previously reported, the behavioural results of this
study confirmed that Exenatide has an impact on feeding
behaviours, showing changes in both calorie consump-
tion and hunger levels in both obese subjects with obesity
and subjects with normal weight (2,3).
Despite the greater reduction in their hunger scores
after Exenatide, the subjects with obesity consumed
more calories than the subjects with normal weights
on both the Exenatide test day and placebo day. This
could point to altered satiety signal processing as sug-
gested by several studies in animals and humans that
have shown obesity-related resistance to satiety signals
such as leptin, insulin and GLP-1 at brain areas associ-
ated with eating control including the hypothalamus
(28,31,32). It is conceivable that the administration of
Figure 3 Functional connectivity analysis of nucleus of the solitary tract (NTS) with thalamus and hypothalamus in obese compared with lean.
(A) The obese group showed increased left NTS functional connectivity with the thalamus and the hypothalamus and (B) compared with the lean
group showed increased right NTS functional connectivity with the left thalamus.
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Exenatide can overcome a baseline obesity-related resis-
tance to GLP-1 satiety signals in women with obesity,
whereas Exenatide in the women with normal weights
may have a more immediate and dramatic impact on
calorie consumption. The observed difference in hunger
levels in the subjects with obesity might also, in part, be
attributed to other factors associated with adiposity and
obesity (33).
When all subjects were combined, a stronger correla-
tion between calorie consumption and functional connec-
tivity of the right NTS with the left hypothalamus was
observed after Exenatide injection. Exenatide has been
shown to increase hypothalamic connectivity with the
rest of the brain in obese non-diabetic male subjects
while the subjects were viewing pictures of food (34). This
study suggests an Exenatide-induced strengthening of
the relationship between NTS connectivity with the hypo-
thalamus and calorie consumption that can be observed
independent of exposure to visual food cues.
All subjects combined also showed a stronger
Exenatide-induced correlation between subject hunger
ratings and functional connectivity between the right
NTS and right hypothalamus. The NTS is a known relay
for vagal information from the gut and projects to the
hypothalamus, which, in turn, communicates with
emotion-regulating and higher cortical centres to gener-
ate sensations of hunger. These study results suggest
the Exenatide-induced functional connectivity between
these regions plays a role in subjective feelings of hunger,
regardless of BMI.
Table 4 Exenatide-induced functional connectivity correlations with appetite measures
A. NTS functional connectivity and calorie consumption
Group Region Coordinate (x,y,z)
Cluster
value (K)
p-value
(family wise error) z-score
L NTS functional connectivity correlation with calorie consumption
Obese L thalamus (20 36 8) 25 0.051 3.74
R thalamus (24 26 16) 8 0.144 3.39
Obese + L thalamus (18 36 10) 16 0.058 3.69
Lean R thalamus (24 24 16) 5 0.200 3.27
R NTS functional connectivity correlation with calorie consumption
Obese R thalamus (0 2 4) 20 0.126 3.45
Obese > L thalamus (8 14 16) 16 0.078 3.38
Lean R thalamus (6 6 12) 15 0.119 3.47
Obese + L HYP (2 4 8) 11 0.008* 3.69
Lean L thalamus (0 2 2) 9 0.030* 3.90
R thalamus (0 2 2) 32 0.064 3.90
B. NTS functional connectivity correlation with hunger ratings
Group Region Coordinate (x,y,z)
Cluster
value (K)
p-value
(family wise error) z-score
L NTS functional connectivity correlation with hunger
Obese L thalamus (20 36 8) 69 0.024* 4.20
R thalamus (24 26 16) 17 0.054 3.94
Obese + L thalamus (20 34 10) 36 0.062 3.67
Lean R thalamus (24 24 16) 9 0.107 3.50
R NTS functional connectivity correlation with hunger
Lean (decreased correlation) L thalamus (16 24 4) 13 0.113 3.48
Obese L thalamus (12 18 18) 23 0.048 3.76
Obese > L thalamus (10 16 16) 75 0.002* 4.76
Lean R thalamus (8 8 12) 17 0.100 3.54
Obese + L HYP (4 2 6) 4 0.022* 3.39
Lean R thalamus (4 4 2) 16 0.083 3.60
All contrasts significant at p 0.001 uncorrected for drug–placebo, RSS3-RSS1 unless otherwise noted.
Functional connectivity of the nucleus of the solitary tract (NTS) seed with the hypothalamus and thalamus were observed to be correlated with
behavioural measures as a result of Exenatide administration. (A) Calorie consumption was observed to be correlated with NTS functional con-
nectivity in the obese group only for the left NTS seed and in both groups combined for the right NTS seed. (B) Subject hunger ratings were
observed to be correlated with NTS functional connectivity in the obese group for the left NTS seed and in the obese group more significantly
than in the lean group in the right NTS. L, left; NTS, nucleus of the solitary tract; R, right.
*p-value observed after correction for multiple comparisons.
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At baseline, before Exenatide administration, there was
a stronger correlation between subjective hunger and
functional connectivity of the right NTS and left thalamus
in the lean compared with the obese group. However,
after Exenatide administration, the obese group demon-
strated a stronger relationship between hunger and
functional connectivity of the NTS with the left thalamus,
suggesting the drug’s greater impact in strengthening
the perhaps depressed engagement of an NTS-based
network with feelings of hunger in the obese group.
Limitations
The current results, obtained in a relatively small sample,
will require validation in a larger sample. Several studies
have reported sex-related brain differences in obesity
and eating behaviour, indicating that women with obesity
have a greater brain response to food in regions
associated with emotional processing and motivation
(35). Larger studies would need to be performed to exam-
ine potential resting state differences between men and
women.
There were also several measurements not collected
that would have helped refine the results of this study.
Resting state data may be influenced by factors beyond
measures used in this study such as gastric emptying or
other satiety hormones. Although the focus of this study
was on analyses using a frequency band less influenced
by physiological noise, autonomic functions have been
demonstrated to effect resting state information (36).
Although we asked subjects to report any feelings of nau-
sea and none did, nausea is a known side effect of GLP-1
agonists and the NTS also plays a role in feelings of
nausea and could impact other brain changes in this
region (37). Also, although the varying levels of blood
Exenatide were considered for these analyses, future
studies would benefit from taking a weighted dosage of
Exenatide based on body fat composition or body weight.
Although BMI is the current clinically used measure of
obesity, it has been argued that other measures such as
visceral fat or waist circumference may be better mea-
sures (38,39). This study also did not take into account
any potential individual variants in the causes of obesity.
Subsequent studies might benefit from examining factors
such as food addiction, genetics, family history and
stress to determine if there are any such measures that
might differentiate the impact of Exenatide on brain
connectivity results.
Summary and clinical implications
The release of several satiety hormones including GLP-1
is stimulated by nutrient ingestion and modulates the
response of the central nervous system to food intake.
GLP-1 stimulation, both in the periphery and within the
brain, can impact the interpretation of hunger and satiety
signalling. An imbalance or misinterpretation of these sig-
nals is thought to play a role in obesity (10). While several
Figure 4 Nucleus of the solitary tract (NTS) functional connectivity correlation analysis with calorie consumption and hunger. (A) All subjects
together showed a positive correlation between calories consumed of a meal and functional connectivity of the right NTS with the right hypo-
thalamus and left thalamus. (B) At baseline before scanning, the lean group showed a greater correlation between hunger and right NTS func-
tional connectivity with the left thalamus. After exenatide injection (versus placebo), (C) all subjects combined had a correlation between hunger
and right NTS functional connectivity with the right hypothalamus and (D) the obese group had a greater correlation between hunger and right
NTS functional connectivity with the left thalamus.
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studies examined the impact of GLP-1 analogues like
Exenatide on stimulated brain responses, few have exam-
ined the impact of the drug on the resting brain. The
current study demonstrates that following the acute
administration of Exenatide, female subjects with obesity
demonstrate a statistically significant decrease in the
subjective feeling of hunger, and an associated increase
in functional connectivity of the NTS, with the hypothala-
mus and thalamus, regions associated with eating behav-
iours. Exenatide also increased the positive correlation
between the NTS-based functional connectivity and
subjective feelings of hunger in all subjects, with a signif-
icantly greater impact in the obese group. As clinical trials
are being conducted by using GLP-1 analogues as a
potential weight loss treatment (9,40), the study of these
hormones and their impact on the brain in obesity and
obesity reduction is key to a complete understanding of
the physiological mechanisms and potential effectiveness
in the clinic.
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Supporting Information
Additional Supporting Information may be found
online in the supporting information tab for this
article.
Figure S1: Post-injection PK values. Both lean and
obese groups had significantly greater levels of
Exenatide in the blood on the day of Exenatide in-
jection compared with placebo injection. They also
both had greater levels of Exenatide 60 min post in-
jection versus 35 min post injection. Comparing
groups, the lean group had greater levels of
Exenatide in their bloodstream both at 35
(p = 0.004) and 60 (p = 0.004) minutes after injec-
tion. *p > 0.05 **p > 0.001
Figure S2: Mean glucose blood levels. Both lean
and obese groups had significantly reduced levels
of mean blood glucose as a result of Exenatide both
35 (lean p = 0.026, obese p = 0.007) and 60 (lean
p = 0.030, obese p = 0.004) minutes post injection
compared with a pre-injection baseline. There were
no significant differences between the lean and
obese groups at any time point
Table S1: Blood levels of Exenatide
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